Gardiquimod

• Description:

  Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs) . Gardiquimod specifically activates TLR7 at concentrations below 10 μM.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Toll-like Receptor (TLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/gardiquimod.html

• Concentration:

  10mM

• Purity:

  99.91

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC (C) (C) CN1C (CNCC) =NC2=C1C3=CC=CC=C3N=C2N

• Molecular Formula:

  C17H23N5O

• Molecular Weight:

  313.40

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29 (6) :907-18.|[2]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369 (2) :298-306.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HIV-1; TLR7; TLR8

• CAS Number:

  1020412-43-4